HomeApplicationsWhy Most Peptide Serums...

Why Most Peptide Serums Don’t Work

Here is a number that should make every peptide serum user pause. Most anti-wrinkle peptides applied to intact skin never reach the dermal layer where they need to work. Mortazavi and Moghimi laid this out clearly in a twenty twenty-two review in the International Journal of Cosmetic Science. The barrier function of human skin is so effective that peptide molecules — relatively large and mostly water-loving — get stopped in the outermost layer. They never meet the fibroblasts or nerve endings they were designed to talk to.

This is not a failure of peptide chemistry. It is a delivery problem. And it sits at the center of a quiet tension in the cosmeceutical world. The lab data on peptides is compelling. Fibroblast cultures respond beautifully. Gene expression shifts in the right direction. But when you put the same peptides in a serum and apply them to a face, the results depend almost entirely on whether the formulation can get them through the skin. Most formulations cannot.

The Stratum Corneum — Your Skin’s Brick Wall

The stratum corneum is the outermost layer of the epidermis. Think of it as a wall of flattened dead cells — corneocytes — packed tightly together and surrounded by lipid bilayers. This structure is brilliant at its job. It keeps water in and pathogens out. It also keeps peptides out.

The lipid matrix between corneocytes is the real gatekeeper. These lipids are highly organized into lamellar sheets that create a tortuous path for any molecule trying to pass through. A molecule must navigate around corneocytes through these narrow lipid channels. The path length is roughly ten to fifteen times the thickness of the stratum corneum itself.

For a molecule to cross this barrier passively, it generally needs three things. A molecular weight below five hundred daltons. A balanced preference for both oil and water environments — what chemists call a log P value between one and three. And no formal charge. Most cosmetic peptides fail on at least two of these criteria and often all three.

Why Peptides Have It Worse Than Other Actives

Peptides are chains of amino acids. The shortest cosmetic peptides contain three to five amino acids. That puts molecular weights in the four hundred to eight hundred dalton range — already at or beyond the passive diffusion limit. Longer peptides like acetyl hexapeptide-8, the famous Argireline, weigh in at around eight hundred ninety daltons.

Size is only the first problem. Most peptide sequences contain charged side chains — lysine, arginine, histidine, glutamic acid, aspartic acid. These charges make the peptide water-soluble. But water-soluble molecules partition poorly into the lipid domains of the stratum corneum. They get stuck on the surface.

There is a third problem that gets less attention. Human skin expresses proteolytic enzymes — peptidases — in the epidermis. These enzymes exist to break down peptide signals as part of normal skin turnover. They do not distinguish between a natural signaling peptide and a cosmetic one. A peptide sitting in the upper epidermis waiting to penetrate is also sitting in an enzymatic degradation zone.

Zdrada-Nowak and colleagues addressed all three of these barriers in a twenty twenty-five review published in the International Journal of Molecular Sciences. They focused on acetyl hexapeptide-8, which they described as hydrophilic with limited permeability through the lipophilic stratum corneum. The review concluded that despite promising cellular data and widespread commercial use, the ability of AH-8 to reach neuromuscular junctions after topical application remains uncertain.

The Numbers Don’t Lie — What Penetration Studies Actually Show

Researchers quantify skin penetration using Franz diffusion cells. These are glass chambers where a piece of excised human or porcine skin separates a donor compartment from a receptor compartment. The formulation goes on top. Whatever makes it through the skin gets collected and measured below.

Hoppel and colleagues at the University of Vienna ran exactly this experiment with acetyl hexapeptide-8 and published their results in the European Journal of Pharmaceutical Sciences. They tested three different emulsion types: a simple oil-in-water cream, a water-in-oil cream, and a complex water-in-oil-in-water multiple emulsion. LC-MS/MS was used for detection, so the measurements are precise down to the nanogram level. The multiple emulsion outperformed both simple emulsions significantly. The water-rich formulations generally outperformed the oil-rich ones.

Neubert and colleagues at Martin Luther University Halle-Wittenberg published an even more striking set of numbers in the European Journal of Pharmaceutics and Biopharmaceutics in twenty eighteen. They measured penetration of the tetrapeptide PKEK from a standard cream versus a nano-sized microemulsion. From the standard cream, forty to fifty-eight percent of the peptide penetrated into the skin. But here is the critical detail. The vast majority stayed in the stratum corneum. It never reached the viable epidermis where it could actually do something.

The microemulsion changed everything. After one hundred minutes, ninety-four percent of the PKEK had penetrated. After three hundred minutes, eighty-eight percent. And this time, a large proportion moved through all skin layers and into the receptor compartment. The nano-sized carrier did not just improve penetration. It fundamentally changed where the peptide ended up.

Chemical Solutions — Palmitoylation, CPPs, and Permeation Enhancers

There are three broad strategies for getting peptides through skin. Chemical modification changes the peptide itself. Carrier systems wrap the peptide in something that can cross. Physical methods punch temporary holes in the barrier.

Palmitoylation is the most common chemical strategy in commercial cosmetics. A sixteen-carbon fatty acid chain — palmitic acid — gets attached to the peptide’s amino terminus. This makes the peptide more lipophilic. It can now partition into the lipid matrix of the stratum corneum. Palmitoyl tripeptide-1, palmitoyl pentapeptide-4, and palmitoyl tetrapeptide-7 all use this approach. The palmitoyl tail is not just a delivery trick. It also helps the peptide anchor to cell membranes once it arrives, which may extend its functional half-life.

Mortazavi and Moghimi reviewed this strategy extensively. The data on palmitoylated peptides like KTTKS — the collagen-stimulating sequence in Matrixyl — showed that the lipid modification substantially improved skin permeation compared to the unmodified peptide. But here they also introduced an important caveat. Palmitoylation helps. It does not solve the problem completely. The modified peptide still faces size constraints and enzymatic degradation.

Cell-penetrating peptides represent a more radical chemical approach. These are short peptide sequences — typically rich in arginine — that evolved or were designed to cross biological membranes. Gautam and colleagues at the CSIR Institute of Microbial Technology in India published a striking demonstration in Scientific Reports in twenty sixteen. They fused a novel cell-penetrating peptide called IMT-P8 to green fluorescent protein — a molecule far larger than any cosmetic peptide. After topical application to mouse skin, the GFP was found in hair follicles and dermal tissue. The same team fused IMT-P8 to a pro-apoptotic peptide and confirmed it retained biological activity inside cells. One peptide acting as a shuttle for another peptide. This is delivery at a completely different level.

Chemical permeation enhancers are the simplest approach. Ethanol, propylene glycol, and various surfactants temporarily disrupt the lipid packing in the stratum corneum. They fluidize the barrier. The effect is modest but real, and many commercial peptide serums rely on these solvents for whatever penetration they achieve.

The Carrier Revolution — Microemulsions, Liposomes, and TRVs

Carrier systems do not change the peptide. They change the vehicle the peptide rides in. This category is where the most exciting recent work has happened.

Microemulsions are thermodynamically stable mixtures of oil, water, and surfactant that form droplets in the ten to one hundred nanometer range. The Neubert study with PKEK used this approach. The tiny droplet size creates an enormous surface area for interaction with the skin surface. The surfactant components help disrupt the lipid barrier. And because the droplets are water-continuous or bicontinuous, they can carry water-soluble peptides through an otherwise hostile lipid environment.

Moradi and colleagues published data in Dermatologic Surgery in twenty twenty-five on a next-generation carrier they call Tiered-Release Vesicles, or TRVs. These are multilamellar vesicles — concentric phospholipid bilayers wrapped around submicron emulsion droplets. The design creates staged release. Outer layers deliver first. Inner layers deliver later. It is the pharmaceutical equivalent of a time-release capsule applied to skin.

The numbers from their study are worth sitting with. TRV formulations delivered a large peptide two to five times more completely into ex vivo human skin than optimized conventional liposomes. For hyaluronic acid — a molecule far larger than any peptide — TRV delivery was three to thirteen times higher than a simple gel. They also published clinical case studies showing reduction of solar elastosis from a topical TRV formulation. That is a visible tissue-level outcome from topical delivery of macromolecules.

Liposomes themselves deserve mention, even though TRVs outperform them. A liposome is a spherical vesicle with a phospholipid bilayer surrounding an aqueous core. The bilayer mimics cell membranes, which allows fusion with the lipid domains of the stratum corneum. The aqueous core holds water-soluble peptides. Standard liposomes improve delivery modestly, typically by a factor of one-and-a-half to two over simple solutions. They are better than nothing. They are not the ceiling.

Physical Routes — Microneedles, Iontophoresis, and Laser-Assisted Delivery

Physical enhancement methods bypass rather than negotiate with the stratum corneum. Microneedles are the most practical for cosmetic use. Arrays of tiny needles — typically two hundred to seven hundred fifty microns long — create microscopic channels through the stratum corneum. The channels are too small to cause pain or bleeding. They are large enough for peptide-sized molecules to pass through.

Mortazavi and Moghimi’s review catalogued microneedle studies across multiple anti-wrinkle peptides. The enhancement ratios are substantial, often ten to one hundred times the passive penetration rate. The limitation is practical. Microneedling is a procedure, not a daily serum. But microneedle patches and at-home roller devices are bringing this closer to a consumer routine.

Iontophoresis uses a mild electric current to drive charged molecules through the skin. Since most peptides carry a net charge at physiological pH, they respond to an electric field. The current also temporarily reduces skin resistance by altering lipid packing. The combination of electrophoresis and barrier disruption produces reliable enhancement. It requires a device, which limits adoption for cosmetics. But the underlying physics is solid.

Laser-assisted delivery takes physical enhancement to the clinical level. Fractional ablative lasers create microscopic columns of destroyed tissue through the epidermis. These columns become highways for topical agents applied immediately after the laser pass. Khalifian and Shisler reviewed this approach in a twenty twenty-six article in Facial Plastic Surgery Clinics of North America. They described how fractional ablative and non-ablative laser systems overcome the stratum corneum barrier to facilitate substantive dermal penetration of bioactive peptides. This is not a home routine. It is a dermatology procedure. But it demonstrates what becomes possible when the barrier is temporarily removed.

Expert Insight — What the Formulation Labels Don’t Tell You

Here is the thing most experienced formulators know and most consumers do not. The peptide concentration printed on a label is the concentration in the bottle. It is not the concentration that reaches the dermis. The difference between those two numbers can be a factor of ten, fifty, or essentially infinite — meaning nothing gets through at all.

A common mistake even within the industry is treating all peptides as equivalent from a delivery perspective. GHK-Cu, the copper peptide, is relatively small at three hundred forty daltons. It has some inherent skin penetration because copper complexation alters its charge distribution. Acetyl hexapeptide-8 is nearly three times larger and far more hydrophilic. Formulating a one percent AH-8 serum in a simple water-glycerin base and calling it a day is, from a delivery standpoint, almost fraudulent. The peptide is sitting on the skin surface.

There is also a timeline reality that marketing language obscures. Most penetration studies measure accumulation over hours — not the thirty seconds between application and the next layer of moisturizer or sunscreen. If you apply a peptide serum and immediately layer something occlusive on top, you might actually be trapping the peptide in the upper stratum corneum rather than helping it penetrate deeper. The occlusion slows water evaporation, which keeps the stratum corneum hydrated. Hydrated corneocytes swell and narrow the intercellular lipid channels. That sounds like it would help. It often makes things worse for large hydrophilic molecules.

Cost is the final silent variable. A properly formulated peptide delivery system — a stable microemulsion, a TRV-based vehicle, a palmitoylated peptide at verified purity — costs significantly more to manufacture than a simple peptide-in-water solution. Brands that sell peptide serums for fifteen dollars are not using advanced delivery systems. They cannot afford to. The peptide they are using may be perfectly good. The vehicle carrying it almost certainly is not.

What This Means for Your Routine

You do not need a laser or a microneedle device to benefit from peptide skincare. But you do need to pay attention to the formulation, not just the ingredient list. Palmitoylated peptides are generally a safer bet than unmodified ones because the lipid tail does real work for penetration. Products that describe their delivery system — microemulsion, liposomal, multilayer vesicle — are signaling that the formulator thought about this problem. Products that do not describe their delivery system probably never solved it.

Application order matters too. Peptides should go on clean, slightly damp skin. Water briefly hydrates the stratum corneum and may improve penetration of water-soluble peptides through the resulting slight swelling of the corneocytes. Wait at least two to three minutes before applying anything on top. Give the peptide vehicle time to do its work before you layer another product over it.

And if you are using a product from Peptide Proof, the formulation question has been asked and answered. Our serums use palmitoylated peptides in vehicles designed with the skin barrier in mind. Not because it is the cheapest way. Because it is the only way that actually delivers.

Further Reading

Share this article: X · LinkedIn · Email

Last reviewed: July 2026. Peptide Proof Editorial Team.

Sources

  1. Mortazavi SM, Moghimi HR. Skin permeability, a dismissed necessity for anti-wrinkle peptide performance. International Journal of Cosmetic Science. 2022 volume 44 issue 2 pages 232 to 248.
  2. Zdrada-Nowak J, Surgiel-Gemza A, Szatkowska M. Acetyl Hexapeptide-8 in Cosmeceuticals — A Review of Skin Permeability and Efficacy. International Journal of Molecular Sciences. 2025 volume 26 issue 12 page 5722.
  3. Moradi A, Bhatia AC, Behr K, Napekoski K, Foldvari M. In Vivo and Ex Vivo Evaluation of a Novel Method for Topical Delivery of Macromolecules Through the Stratum Corneum for Cosmetic Applications. Dermatologic Surgery. 2025 volume 51 issue 4 pages 403 to 408.
  4. Neubert RHH, Sommer E, Schölzel M, Tuchscherer B, Mrestani Y, Wohlrab J. Dermal peptide delivery using enhancer molecules and colloidal carrier systems. Part II: Tetrapeptide PKEK. European Journal of Pharmaceutics and Biopharmaceutics. 2018 volume 124 pages 28 to 33.
  5. Hoppel M, Reznicek G, Kählig H, Kotisch H, Resch GP, Valenta C. Topical delivery of acetyl hexapeptide-8 from different emulsions: influence of emulsion composition and internal structure. European Journal of Pharmaceutical Sciences. 2015 volume 68 pages 27 to 35.
  6. Gautam A, Nanda JS, Samuel JS, Kumari M, Priyanka P, Bedi G, Nath SK, Mittal G, Khatri N, Raghava GP. Topical Delivery of Protein and Peptide Using Novel Cell Penetrating Peptide IMT-P8. Scientific Reports. 2016 volume 6 page 26278.
  7. Khalifian S, Shisler J. Photobiomodulation and Biological Pathways in Skin Regeneration and Rejuvenation. Facial Plastic Surgery Clinics of North America. 2026 volume 34 issue 3 pages 471 to 485.

- A word from our sponsors -

spot_img

Most Popular

LEAVE A REPLY

Please enter your comment!
Please enter your name here

More from Author

多肽相关试验与供应信息的公开化:CTIS 与短缺数据库怎么用

信息日期:2026年9月22日 — 在多肽相关领域,监管透明化持续推进:欧盟临床试验信息通过 CTIS 公开登记与结果摘要,美国 FDA 维护药品短缺数据库并发布供应信息。这些机制把试验状态与短缺记录放进可检索的公共档案,改变了企业披露节奏和市场预期的形成方式。 对需要据此作出经营、合规或采购决定的人来说,真正的问题不是记住一个结论,而是先确认它适用于谁、通过什么环节影响实际业务,以及哪项证据足以支持行动。 事实与适用范围 在多肽相关领

含铜肽护肤品的合规框架:成分清单与宣称规则如何变化

信息日期:2026年9月22日 — 在多数市场,含铜肽(GHK-Cu)的护肤品按化妆品管理,需符合成分禁限用清单、标签与宣称规则;原料能否使用取决于当地清单状态与浓度限制,而非分子本身的功能描述。监管更新通常通过清单修订与过渡期落地,企业需要在过渡期内完成配方或文案调整。 对需要据此作出经营、合规或采购决定的人来说,真正的问题不是记住一个结论,而是先确认它适用于谁、通过什么环节影响实际业务,以及哪项证据足以支持行动。 事实与适用范围 在

多肽产业链的产能与订单:把规划产能当成已投产的常见误判

信息日期:2026年9月22日 — 多肽产业链上游是氨基酸、树脂与试剂,中游是固相与液相合成的生产与 CDMO 产能,下游覆盖药品、化妆品与诊断。产能扩张周期长、洁净与质量体系要求高,供给节奏由订单结构、产能利用率与原料价格共同决定,而不是由需求热度单独决定。 对需要据此作出经营、合规或采购决定的人来说,真正的问题不是记住一个结论,而是先确认它适用于谁、通过什么环节影响实际业务,以及哪项证据足以支持行动。 事实与适用范围 多肽产业链上游

多肽应用落地的分类难题:化妆品、诊断与药品的质量门槛

信息日期:2026年9月22日 — 多肽在应用端常见于护肤原料、体外诊断试剂、组织工程涂层、食品与饲料添加剂以及药物载体。同一序列在不同用途下受不同监管框架约束,身份、纯度、杂质谱与允许宣称的内容差别很大,原料并不能简单跨用途平移使用。 对需要据此作出经营、合规或采购决定的人来说,真正的问题不是记住一个结论,而是先确认它适用于谁、通过什么环节影响实际业务,以及哪项证据足以支持行动。 事实与适用范围 多肽在应用端常见于护肤原料、体外诊断试

- A word from our sponsors -

spot_img

Read Now

多肽相关试验与供应信息的公开化:CTIS 与短缺数据库怎么用

信息日期:2026年9月22日 — 在多肽相关领域,监管透明化持续推进:欧盟临床试验信息通过 CTIS 公开登记与结果摘要,美国 FDA 维护药品短缺数据库并发布供应信息。这些机制把试验状态与短缺记录放进可检索的公共档案,改变了企业披露节奏和市场预期的形成方式。 对需要据此作出经营、合规或采购决定的人来说,真正的问题不是记住一个结论,而是先确认它适用于谁、通过什么环节影响实际业务,以及哪项证据足以支持行动。 事实与适用范围 在多肽相关领

含铜肽护肤品的合规框架:成分清单与宣称规则如何变化

信息日期:2026年9月22日 — 在多数市场,含铜肽(GHK-Cu)的护肤品按化妆品管理,需符合成分禁限用清单、标签与宣称规则;原料能否使用取决于当地清单状态与浓度限制,而非分子本身的功能描述。监管更新通常通过清单修订与过渡期落地,企业需要在过渡期内完成配方或文案调整。 对需要据此作出经营、合规或采购决定的人来说,真正的问题不是记住一个结论,而是先确认它适用于谁、通过什么环节影响实际业务,以及哪项证据足以支持行动。 事实与适用范围 在

多肽产业链的产能与订单:把规划产能当成已投产的常见误判

信息日期:2026年9月22日 — 多肽产业链上游是氨基酸、树脂与试剂,中游是固相与液相合成的生产与 CDMO 产能,下游覆盖药品、化妆品与诊断。产能扩张周期长、洁净与质量体系要求高,供给节奏由订单结构、产能利用率与原料价格共同决定,而不是由需求热度单独决定。 对需要据此作出经营、合规或采购决定的人来说,真正的问题不是记住一个结论,而是先确认它适用于谁、通过什么环节影响实际业务,以及哪项证据足以支持行动。 事实与适用范围 多肽产业链上游

多肽应用落地的分类难题:化妆品、诊断与药品的质量门槛

信息日期:2026年9月22日 — 多肽在应用端常见于护肤原料、体外诊断试剂、组织工程涂层、食品与饲料添加剂以及药物载体。同一序列在不同用途下受不同监管框架约束,身份、纯度、杂质谱与允许宣称的内容差别很大,原料并不能简单跨用途平移使用。 对需要据此作出经营、合规或采购决定的人来说,真正的问题不是记住一个结论,而是先确认它适用于谁、通过什么环节影响实际业务,以及哪项证据足以支持行动。 事实与适用范围 多肽在应用端常见于护肤原料、体外诊断试

多肽机制研究的读数层级:亲和力高为什么不等于体内有效

信息日期:2026年9月22日 — 多肽通过与受体、酶或金属离子结合发挥功能,机制研究常用表面等离子共振、报告基因细胞系与结构解析测定亲和力和下游信号。这些指标描述的是分子识别与通路激活,而体内效果还取决于暴露量、半衰期、组织分布与清除途径,两层数据不能互相替代。 对需要据此作出经营、合规或采购决定的人来说,真正的问题不是记住一个结论,而是先确认它适用于谁、通过什么环节影响实际业务,以及哪项证据足以支持行动。 事实与适用范围 多肽通过与

多肽护肤抗衰:体外胶原信号与人体皱纹证据之间的差距

信息日期:2026年9月22日 — 多肽抗衰产品常引用成纤维细胞体外实验与胶原合成通路数据,宣称刺激胶原、减少皱纹。这类结果多来自单一细胞模型、高浓度直接接触或短期小样本人体研究,终点通常是仪器测得的皮肤参数,而非长期结构性改变,因此与消费者理解的“逆龄”不是同一层级的证据。 对需要据此作出经营、合规或采购决定的人来说,真正的问题不是记住一个结论,而是先确认它适用于谁、通过什么环节影响实际业务,以及哪项证据足以支持行动。 事实与适用范围

规则解读:临床试验登记与结果披露收紧后的研究合规动作

信息日期:2026年9月21日 — 多国已把临床试验登记与结果披露设为法定或准法定义务,要求研究开始前登记、结束后在限期内提交结果摘要,并对未按时披露设置处罚或资助限制。这类要求同样覆盖以多肽为干预的早期与探索性研究。 对需要据此作出经营、合规或采购决定的人来说,真正的问题不是记住一个结论,而是先确认它适用于谁、通过什么环节影响实际业务,以及哪项证据足以支持行动。 事实与适用范围 多国已把临床试验登记与结果披露设为法定或准法定义务,要求

规则解读:合成肽在药品注册中的归类判定与资料口径

信息日期:2026年9月21日 — 合成肽在多数法规体系中通常按化学药物而非生物制品管理,但当其由生物技术方法生产、含非天然结构或采用酶法与重组片段时,归类判定可能改变,进而影响申报模板、生产场地检查方式与数据保护适用。 对需要据此作出经营、合规或采购决定的人来说,真正的问题不是记住一个结论,而是先确认它适用于谁、通过什么环节影响实际业务,以及哪项证据足以支持行动。 事实与适用范围 合成肽在多数法规体系中通常按化学药物而非生物制品管理,

长序列多肽合成:从树脂载量到纯化收率的工艺账

信息日期:2026年9月21日 — 固相合成中每一步偶联效率再高也会累积损失,长序列总收率约等于各步收率相乘。树脂载量、氨基酸当量、偶联试剂与裂解条件共同决定粗肽纯度,而纯化与冻干环节通常才决定最终可交付量,报价应以此为基础核算。 对需要据此作出经营、合规或采购决定的人来说,真正的问题不是记住一个结论,而是先确认它适用于谁、通过什么环节影响实际业务,以及哪项证据足以支持行动。 事实与适用范围 固相合成中每一步偶联效率再高也会累积损失,长

多肽不是小分子:把类似物思维带进研发要付的三个代价

信息日期:2026年9月21日 — 行业里常见一种默认假设:改一个氨基酸就像改小分子的一个取代基,活性可以线性外推。但多肽的构象、聚集倾向、蛋白酶稳定性与免疫原性往往由整段序列共同决定,单点改动可能同时改变多个性质,也可能牵动工艺与杂质谱。 对需要据此作出经营、合规或采购决定的人来说,真正的问题不是记住一个结论,而是先确认它适用于谁、通过什么环节影响实际业务,以及哪项证据足以支持行动。 事实与适用范围 行业里常见一种默认假设:改一个氨基

多肽原料药产能扩张:CDMO订单结构与报价口径怎么读

信息日期:2026年9月21日 — 多肽原料药需求增长主要来自代谢与体重管理相关品种。产能瓶颈集中在线性固相合成所用的树脂、氨基酸原料与纯化冻干设备。行业公开信息通常是CDMO的产能公告、批次规模与在建产线,而不是单价,因为单价随序列长度、纯度与批量剧烈变化。 对需要据此作出经营、合规或采购决定的人来说,真正的问题不是记住一个结论,而是先确认它适用于谁、通过什么环节影响实际业务,以及哪项证据足以支持行动。 事实与适用范围 多肽原料药需求

多肽在诊断试剂与成像探针中的应用边界

信息日期:2026年9月21日 — 多肽在诊断与成像中的常见用法是作为靶向配体,把荧光、放射性或磁性标记带到特定受体或蛋白上。它的价值来自可化学合成、序列可调、组织穿透相对快,但亲和力与血浆稳定性通常不如成熟抗体,需要逐项目验证并做对照。 对需要据此作出经营、合规或采购决定的人来说,真正的问题不是记住一个结论,而是先确认它适用于谁、通过什么环节影响实际业务,以及哪项证据足以支持行动。 事实与适用范围 多肽在诊断与成像中的常见用法是作为靶